ATE183514T1 - Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten - Google Patents

Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten

Info

Publication number
ATE183514T1
ATE183514T1 AT93913627T AT93913627T ATE183514T1 AT E183514 T1 ATE183514 T1 AT E183514T1 AT 93913627 T AT93913627 T AT 93913627T AT 93913627 T AT93913627 T AT 93913627T AT E183514 T1 ATE183514 T1 AT E183514T1
Authority
AT
Austria
Prior art keywords
human
protein
pct
lymphocytes
peptides
Prior art date
Application number
AT93913627T
Other languages
English (en)
Inventor
Cornelis Joseph Maria Melief
Wybe Martin Kast
Original Assignee
Univ Leiden
Seed Capital Investments
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden, Seed Capital Investments filed Critical Univ Leiden
Application granted granted Critical
Publication of ATE183514T1 publication Critical patent/ATE183514T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT93913627T 1992-05-26 1993-05-18 Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten ATE183514T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92201510 1992-05-26

Publications (1)

Publication Number Publication Date
ATE183514T1 true ATE183514T1 (de) 1999-09-15

Family

ID=8210629

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93913627T ATE183514T1 (de) 1992-05-26 1993-05-18 Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten

Country Status (11)

Country Link
US (1) US5679641A (de)
EP (1) EP0643726B1 (de)
JP (2) JPH08501280A (de)
AT (1) ATE183514T1 (de)
AU (1) AU681853B2 (de)
CA (1) CA2136624A1 (de)
DE (1) DE69326064T2 (de)
DK (1) DK0643726T3 (de)
ES (1) ES2139012T3 (de)
GR (1) GR3031919T3 (de)
WO (1) WO1993024525A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509251A (ja) * 1992-07-22 1995-10-12 ザ トラスティーズ オブ プリンストン ユニバーシティ ｐ５３ワクチン
FR2698367B1 (fr) * 1992-11-02 1995-02-17 Eurobio Lab Fragments de la protéine p53 et leurs utilisations dans la détection et le suivi d'états pathologiques.
EP0703783B1 (de) * 1993-03-05 2010-05-05 Epimmune Inc. Verfahren zur herstellung von immunogenen hla-a2.1-bindenden peptiden
CA2168950A1 (en) * 1993-08-06 1995-02-16 Esteban Celis Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
FR2722207B1 (fr) * 1994-07-07 1996-09-27 Inst Nat Sante Rech Med Methode pour generer une population de cellules presentant a leur surface une forte densite d'un pepride exogene specifique associe azx molecules du cmh; population de cellules
JPH10510988A (ja) 1994-12-14 1998-10-27 ザ スクリップス リサーチ インスティテュート 腫瘍−特異的細胞毒性ｔ細胞のインビボ活性化
US5925799A (en) * 1996-03-12 1999-07-20 Abb Lummus Global Inc. Catalytic distillation and hydrogenation of heavy unsaturates in an olefins plant
CA2250166A1 (en) * 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
SE9604581D0 (sv) * 1996-12-12 1996-12-12 Karolinska Innovations Ab An agent against cancer and virus infections
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
IL138214A0 (en) * 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
SE9801695D0 (sv) * 1998-05-14 1998-05-14 Karolinska Innovations Ab Inhibition of p53 function by a p53-derived peptide
EP2036573A1 (de) * 1998-06-17 2009-03-18 IDM Pharma, Inc. HLA-bindende Peptide und ihre Verwendungen
AU3755800A (en) * 1999-03-15 2000-10-04 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
TW410377B (en) * 1999-06-17 2000-11-01 Taiwan Semiconductor Mfg Method of planarization and the apparatus of the same
WO2001018035A2 (en) * 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
FR2794368A1 (fr) * 1999-10-07 2000-12-08 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
US20040048790A1 (en) * 1999-12-10 2004-03-11 John Fikes Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
AU7524601A (en) * 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
DE10109855A1 (de) * 2001-03-01 2002-09-12 Stanislawski Thomas Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung
DE60228504D1 (de) * 2001-06-05 2008-10-02 Altor Bioscience Corp P53 bindende t-zellrezeptormoleküle und deren verwendungen
WO2003006043A1 (en) * 2001-07-10 2003-01-23 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
CA2493081C (en) * 2002-07-12 2013-04-23 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
WO2006124700A2 (en) * 2005-05-12 2006-11-23 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
WO2007030451A2 (en) * 2005-09-07 2007-03-15 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
US20110053849A1 (en) * 2006-08-17 2011-03-03 Salomon Amar Regulation of litaf modulated cytokine production by a novel p53 short peptide
AU2008210434C8 (en) 2007-01-31 2014-03-27 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
BRPI0809366B8 (pt) 2007-03-28 2021-05-25 Harvard College polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
US8859723B2 (en) 2010-08-13 2014-10-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
US10905739B2 (en) 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
EP3347372A4 (de) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. Peptidomimetische makrocyclen als modulatoren von mcl-1
US20200316121A1 (en) * 2017-09-29 2020-10-08 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN114651001A (zh) * 2019-11-07 2022-06-21 武汉华大吉诺因生物科技有限公司 肿瘤免疫治疗多肽及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet

Also Published As

Publication number Publication date
EP0643726B1 (de) 1999-08-18
DK0643726T3 (da) 2000-03-20
DE69326064D1 (de) 1999-09-23
ES2139012T3 (es) 2000-02-01
US5679641A (en) 1997-10-21
AU681853B2 (en) 1997-09-11
AU4359193A (en) 1993-12-30
EP0643726A1 (de) 1995-03-22
JPH08501280A (ja) 1996-02-13
WO1993024525A1 (en) 1993-12-09
DE69326064T2 (de) 2000-05-25
GR3031919T3 (en) 2000-03-31
CA2136624A1 (en) 1993-12-09
JP2004123708A (ja) 2004-04-22

Similar Documents

Publication Publication Date Title
ATE183514T1 (de) Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten
IL105554A0 (en) Peptides of human papilloma virus for use in human t cell response inducing compositions
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
AU7079396A (en) Anti-galalpha(1,3)gal antibody binding peptides
AU2987695A (en) Interruption of binding of mdm2 and p53 protein and therapeutic application thereof
EP0334165A3 (en) Monoclonal antibodies
MX9703642A (es) Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
EP1071443A4 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
HK1031994A1 (en) Methods for detection and treatment of individuals having abnormal cells expressing hla-a2/tyrosinase peptide antigens
GR3001922T3 (en) Use of n,n'-bis-l-amino acid-l-cystin peptides in amino acid preparations for oral and parenteral administration
FR2724320B1 (fr) Nouvel implant pour le traitement des maladies acquises
TR199700842T1 (xx) �nsan DNase I Varyantlar�.
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
AU1318797A (en) Peptides and uses thereof for therapy of celiac diseases
BG101846A (en) HUMAN DNase I VARIANTS
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
MX9700199A (es) Composiciones de cadena invariante utiles para tratar enfermedades autoinmunes.
BG101847A (en) Human dnase i variants

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee